Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON‐PFT Extension I Trials
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Bone and Mineral Research"
DOI: 10.1002/jbmr.3654
Abstract: An ASBMR Task Force recommends a drug holiday for certain women treated for ≥5 years with oral alendronate or ≥3 years with intravenous zoledronic acid, with reassessment 2 to 3 years later. It is not… read more here.
Keywords: bmd; changes bone; zoledronic acid; horizon pft ... See more keywords
What Else Do We Need? A Commentary on Zoledronate Effects on Cancer and Cardiac Events
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Bone and Mineral Research"
DOI: 10.1002/jbmr.3880
Abstract: The devastating consequences of skeletal fragility are well known, as are the unequivocal benefits of prescribing osteoporosis medications to patients who are at increased risk of fracture. Nonetheless, those of us who focus on treating… read more here.
Keywords: death; zoledronic acid; group; mortality ... See more keywords
Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures
Sign Up to like & getrecommendations! Published in 2017 at "Osteoporosis International"
DOI: 10.1007/s00198-017-4108-y
Abstract: To the editor, Cases have recently been published about reboundassociated vertebral fractures (RAVFs) after discontinuation of denosumab in patients with postmenopausal osteoporosis [1]. Denosumab therapy lasted between 6 and 42 months, and clinical spontaneous fractures… read more here.
Keywords: switching denosumab; denosumab; discontinuation denosumab; vertebral fractures ... See more keywords
Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis
Sign Up to like & getrecommendations! Published in 2018 at "Osteoporosis International"
DOI: 10.1007/s00198-018-04833-3
Abstract: SummaryTreatment with zoledronic acid 5 mg maintained bone turnover markers in the premenopausal range, increased lumbar spine bone mineral density, and maintained hip bone mineral density in women previously treated with odanacatib 50 mg weekly.IntroductionThe development of… read more here.
Keywords: treatment; treatment zoledronic; bone loss; zoledronic acid ... See more keywords
Addition of dexamethasone to manage acute phase responses following initial zoledronic acid infusion
Sign Up to like & getrecommendations! Published in 2020 at "Osteoporosis International"
DOI: 10.1007/s00198-020-05653-0
Abstract: Acute phase response (APR), including myalgia, influenza-like symptoms, headache, arthralgia, and pyrexia, is the most common adverse reaction to initial zoledronic acid infusion. Dexamethasone plus acetaminophen is effective in significantly reducing the incidence and severity… read more here.
Keywords: acute phase; infusion; group; study group ... See more keywords
Cost-effectiveness of 3 versus 6 years of zoledronic acid treatment before bisphosphonate holiday for women with osteoporosis
Sign Up to like & getrecommendations! Published in 2021 at "Osteoporosis International"
DOI: 10.1007/s00198-021-06010-5
Abstract: We evaluated the cost-effectiveness of recurrent periods of 3 versus 6 years of zoledronic acid treatment prior to 3-year bisphosphonate holidays for US postmenopausal women with osteoporosis and femoral neck BMD T-scores between − 2.5 and − 3.5. We… read more here.
Keywords: years zoledronic; treatment; acid treatment; zoledronic acid ... See more keywords
Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-021-04262-w
Abstract: Switch from zoledronic acid (ZA) to denosumab may increase the risk of medication-related osteonecrosis of the jaw (MRONJ) owing to the additive effect of denosumab on the jawbone and residual ZA activities. We evaluated the… read more here.
Keywords: bone metastases; risk developing; denosumab; zoledronic acid ... See more keywords
An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries
Sign Up to like & getrecommendations! Published in 2017 at "Supportive Care in Cancer"
DOI: 10.1007/s00520-017-3697-5
Abstract: PurposeDenosumab (administered via subcutaneous injection) demonstrated superior efficacy versus the intravenously administered zoledronic acid in the prevention of skeletal-related events in an integrated analysis of three head-to-head phase III trials in patients with bone metastases… read more here.
Keywords: time motion; time; observational time; zoledronic acid ... See more keywords
Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases
Sign Up to like & getrecommendations! Published in 2021 at "Supportive Care in Cancer"
DOI: 10.1007/s00520-021-06018-x
Abstract: This study aimed to evaluate the association between clinical characteristics and development of medication-related osteonecrosis of the jaw (MRONJ) in patients who underwent dental examinations before the initiation of treatment with denosumab or zoledronic acid,… read more here.
Keywords: zoledronic acid; denosumab zoledronic; treatment; bone metastases ... See more keywords
Long-term outcome of (neo)adjuvant zoledronic acid therapy in locally advanced breast cancer
Sign Up to like & getrecommendations! Published in 2021 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-021-06100-2
Abstract: The role of zoledronic acid (ZOL), a bone-targeted bisphosphonate, in the treatment of patients with breast cancer remains an active area of study. Here, we report the long-term outcomes of a randomized placebo-controlled phase II… read more here.
Keywords: zoledronic acid; advanced breast; breast cancer; cancer ... See more keywords
Cytotoxic and anti-angiogenic effects of zoledronic acid in DU-145 and PC-3 prostate cancer cell lines.
Sign Up to like & getrecommendations! Published in 2020 at "Molecular biology reports"
DOI: 10.1007/s11033-020-05840-6
Abstract: This study aims to investigate the apoptotic and anti-angiogenic effect of Zoledronic acid on hormone-refractory prostate cancer cell lines. XTT cell proliferation assay used to assess cytotoxicity. Caspase 3/7 activity and DNA fragmentation were measured… read more here.
Keywords: zoledronic acid; cell lines; cell; prostate cancer ... See more keywords